Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.73 -0.37 (-1.84%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Where Apellis Pharmaceuticals Stands With Analysts ↗

March 07, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Apellis Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Apellis Pharmaceuticals's Earnings Outlook ↗

February 25, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement....

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

January 11, 2022

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder ↗

December 15, 2021

The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan...

Via Benzinga

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗

December 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...

Via Benzinga

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

December 08, 2021

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Analyst Ratings For Apellis Pharmaceuticals ↗

November 29, 2021

Over the past 3 months, 8 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗

November 29, 2021

Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:

Via Benzinga

The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment ↗

November 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 15, 2021

Gainers Kezar Life Sciences (NASDAQ:KZR) s...

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

November 09, 2021

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Cramer Likes DraftKings, Skyworks, And These Automakers ↗

October 07, 2021

On CNBC's "Mad Money Lightning Rou...

Via Benzinga

Better Pharmaceutical Stock: Apellis or Novartis? ↗

September 15, 2021

The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments.

Via Talk Markets

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside ↗

September 13, 2021

Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:

Via Benzinga

60 Biggest Movers From Friday ↗

September 13, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...

Via Benzinga

Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher ↗

September 10, 2021

Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86. The U.S. has...

Via Benzinga

Topics Stocks

What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

September 10, 2021

Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

8 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

September 10, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today ↗

September 10, 2021

Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results.

Via InvestorPlace

Dow Eyes Fifth-Straight Skid, Another Weekly Drop ↗

September 10, 2021

The Dow Jones Industrial Index is giving up its earlier gains, last seen down 149 points, as investors fail to shake off the economic uncertainty that's blanketed the holiday-shortened week.

Via Talk Markets

Topics Stocks

Why Apellis Pharmaceutical Shares Are Plunging Today ↗

September 10, 2021

Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 10, 2021

Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge ↗

September 10, 2021

Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the...

Via Benzinga

Topics Stocks

41 Stocks Moving In Friday's Mid-Day Session ↗

September 10, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic...

Via Benzinga

Here's Why Iveric Bio Stock Is Rocketing Higher Today ↗

September 10, 2021

Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.

Via The Motley Fool

ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio ↗

September 10, 2021

IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today.

Via InvestorPlace

Here's Why Apellis Pharmaceuticals Is Getting Hammered Today ↗

September 10, 2021

Conflicting clinical trial results for the company's lead candidate are to blame.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

All News about Apellis Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today